Ingrown Toenails: Symptoms, Diagnosis, Treatment & Red Flags

An ingrown toenail—onychocryptosis or unguis incarnatus—is a mechanical and inflammatory disorder in which the lateral edge of the nail plate breaches the epidermal barrier of the adjacent nail fold. The penetrating spicule acts as a chronic foreign body: it triggers neutrophil infiltration, lymphangitic erythema, hyperkeratosis of the fold and—if left untreated—exuberant granulation tissue, secondary bacterial colonisation and lateral wall hypertrophy that walls the offending nail edge in even tighter.

The hallux carries roughly four-fifths of cases because it sees the highest cumulative loading at heel-strike, the broadest nail plate and the tightest soft-tissue envelope at the lateral fold. Adolescents and young adults dominate the first peak (sweat, sport, growth-related nail-bed changes and fashion-driven footwear), and a smaller second peak appears in older adults whose comorbid disease, gait abnormality and reduced self-care collide with thicker, more curved nail plates.

Onychocryptosis is a clinical diagnosis—imaging and laboratory tests have almost no role unless deeper infection, drug-induced disease or a differential such as gouty arthropathy, subungual exostosis or amelanotic melanoma is in play. The diagnostic energy belongs in staging severity and stratifying host risk, not in over-investigating a nail.

The Heifetz classification is the most widely used bedside scheme and drives every meaningful management decision. Mosaic and Frost variants exist, but for ward and primary-care teams Heifetz is the lingua franca; it reads in seconds, transmits cleanly between clinicians and predicts which patients will respond to conservative care versus need procedural management.

↔On a small screen, swipe or scroll sideways to see the full table.

Two practical refinements help. First, separate infected stage II disease from granulating stage III rather than blurring them—infection is microbial, granulation is anatomical, and the durable answer to granulation is matricectomy regardless of whether the swab grows anything. Second, identify high-risk hosts (diabetes, neuropathy, peripheral arterial disease, immunosuppression, paediatric cases needing sedation) and bump them up the urgency scale even if the local stage looks unremarkable.

Most patients describe a slow build of toe-end discomfort that escalates from annoying when I push off in trainers to severe focal pain that disrupts sleep and work. Acute presentations after pedicure trauma or a tight new shoe are common; a small minority arrive with cellulitis already tracking up the dorsum.

Typical features

• Localised lateral fold pain—worst at the corner of the nail, exacerbated by pressure and warm shoes.
• Erythema and oedema of the affected fold; tenderness on light pinch testing of the lateral nail edge.
• Hyperkeratosis at the fold edge; visible spicule of nail penetrating the soft tissue.
• Serous or purulent discharge that may be intermittent; crusting around the lateral nail margin.
• Hypertrophic granulation tissue—friable, bleeds on touch—in chronic stage III disease.
• Pain referred along the digit during gait, leading to antalgic foot positioning and adaptive callus on the lateral border.

Atypical or higher-risk presentations

• Multiple concurrent toes with periungual inflammation—think drug-induced disease (retinoids, EGFR or MEK inhibitors) rather than mechanical onychocryptosis.
• Painless ulceration in a patient with peripheral neuropathy—classical diabetic neuropathic ulcer pattern; never assume the patient will report pain reliably.
• Bluish-black discolouration extending under the nail plate—rule out subungual haematoma, melanonychia or an amelanotic melanoma, particularly in older adults with no clear trauma.
• Spreading erythema beyond the digit, lymphangitic streaks, fever, or systemic symptoms—treat as cellulitis with deep-tissue or bone risk.
• Loss of pulse, capillary refill >3 s, dusky cool toe—escalate as ischaemic limb until proven otherwise.

Onychocryptosis is a mechanical disorder amplified by host and environmental factors. Most patients have several risk modifiers stacked on top of each other rather than a single cause, which is why education without addressing the dominant trigger usually fails.

Mechanical and behavioural drivers

• Improper trimming—curved cuts or excessively short nails leave a sharp lateral spicule that pierces the fold as the nail grows.
• Tight or pointed footwear, narrow toe boxes, ill-fitting trainers—chronically compress the lateral fold against the nail edge.
• Repeated trauma—ballet, football, running and rugby; stubbing injury; dropping objects on the toe.
• Aggressive pedicure—particularly with curved cuticle nippers and over-zealous nail-fold cleaning.
• Chronic moisture and hyperhidrosis—soft, macerated soft tissue is more easily breached by a sharp nail edge; common in athletes and occupational footwear.

Anatomical and host factors

• Genetic nail-plate curvature—involuted and pincer nails are intrinsically prone to lateral fold conflict.
• Hallux valgus, foot biomechanics, gait abnormality—altered loading on the great toe.
• Obesity—increased mechanical pressure and impaired wound healing.
• Adolescent growth and sweat changes—drives the first incidence peak.
• Concurrent tinea pedis or onychomycosis—soggy, thickened nails change the geometry and softness of the nail-fold environment.

Drug-induced patterns

• Systemic retinoids (isotretinoin, acitretin) and oral terbinafine in some series.
• EGFR inhibitors (cetuximab, panitumumab, erlotinib, gefitinib) and MEK inhibitors—exuberant granulation across multiple toes simultaneously.
• Indinavir and certain other antiretrovirals; taxanes; capecitabine.

Comorbid risk amplifiers

• Diabetes mellitus—microvascular disease, neuropathy and impaired wound healing transform a routine ingrown toe into an amputation pathway. Sub-stratify with current HbA1c and pedal pulse status.
• Peripheral arterial disease—any patient with absent pedal pulses, claudication or known PAD needs vascular and surgical input before instrumentation.
• Immunosuppression—steroids, biologics, chemotherapy, post-transplant immunosuppression, advanced HIV.
• Anticoagulation—does not preclude partial nail avulsion under appropriate technique, but plan haemostasis and review need-to-hold per local pathway.

Diagnosis is clinical. The energy belongs in stratifying severity, host risk and comorbid foot pathology rather than in laboratory or imaging work-up.

Focused history

• Onset, recurrence pattern, prior episodes and prior interventions; any history of nail surgery.
• Footwear and activity (running, ballet, contact sport, occupational steel-toe boots).
• Trimming and pedicure habits; recent trauma.
• Medical history—diabetes, peripheral arterial disease, immunosuppression, anticoagulation, allergies (especially to local anaesthetic and topical antiseptics).
• Drug history—retinoids, EGFR/MEK inhibitors, taxanes, indinavir.
• Tetanus immunisation status when there is open skin breakdown.

Targeted examination

• Identify the affected nail fold—lateral, medial or both—and assess granulation, hyperkeratosis and discharge.
• Probe gently for a spicule of nail entering the soft tissue.
• Check capillary refill, distal sensation (light touch and 10 g monofilament), dorsalis pedis and posterior tibial pulses, and skin temperature.
• Examine the contralateral foot and the other toes for occult disease, fungal change, callus pattern and biomechanical clues.
• Document with a clinical photograph for serial comparison.

When to add tests

• Wound swab via a structured wound culture when systemic features, treatment failure, immunosuppression or healthcare-associated risk make targeted antibiotic stewardship matter.
• Bloods—CBC, CRP and HbA1c when systemic infection, diabetic-foot pathway entry or unexplained recurrence is on the table.
• Plain radiograph when osteomyelitis or subungual exostosis is suspected; MRI under specialist input if osteomyelitis is likely but plain films are equivocal.
• Vascular assessment—ankle-brachial index, Doppler ultrasound or formal vascular review when pulses are absent, ABI <0.9 or claudication is reported.
• Biopsy—rare; reserved for atypical pigmentation, refractory granulation or a mass in the nail fold.

The pragmatic chain a triage nurse, urgent-care clinician or primary-care prescriber can run from the door:

1. Screen host risk first. Diabetes, neuropathy, PAD, immunosuppression, anticoagulation, paediatric procedural sedation needs—if any apply, the threshold for specialist review drops sharply.
2. Stage the toe. Heifetz I, II or III; document granulation, discharge and hyperkeratosis.
3. Stage I → conservative care. Soak-and-wick, lateral fold tape, footwear and trimming counselling, analgesia, review at 2–3 weeks; refer if no progress.
4. Stage II → procedure rather than oral antibiotics first. Partial nail avulsion in clinic under digital ring block; reserve oral antibiotics for spreading cellulitis, systemic features or comorbid risk that justifies cover.
5. Stage III → partial nail avulsion plus chemical matricectomy. Phenol 88% or sodium hydroxide 10% as per local protocol; this is the recurrence-lowering step that conservative care cannot replace.
6. Comorbid risk → escalate. Diabetic foot pathway, vascular review, paediatric or surgical referral as relevant; do not improvise out-of-hours nail surgery on a fragile foot.
7. Safety-net every patient. Same-day return for spreading erythema, fever, throbbing pain after 48 hours, dark or black tissue, foul discharge or new toe numbness.

↔On a small screen, swipe or scroll sideways to see the full table.

Conservative care for stage I (and selected early stage II without infection)

• Warm-water soaks—10–15 minutes twice daily, with or without dilute antiseptic; softens the lateral fold and reduces inflammation.
• Cotton or dental-floss wicking—a small wisp of cotton or sterile floss tucked between the lateral nail edge and the soft tissue after each soak, advanced as the spicule grows out.
• Lateral fold taping—elastic adhesive tape pulled diagonally away from the nail edge, holding the fold open while it heals.
• Gutter splint—a flexible plastic sleeve, sometimes secured with adhesive or a single suture, positioned between the lateral nail edge and the soft tissue while the nail grows out; useful in painful uninfected stage I/II disease.
• Footwear and trimming counselling—wider toe box, straight-cut trims to nail-edge level, no aggressive lateral cleaning.
• Analgesia—oral ibuprofen or naproxen, or acetaminophen if NSAIDs are contraindicated; topical lidocaine gel for short-term symptom relief between dressings.
• Topical potent corticosteroid or timolol 0.5% solution—selected hypergranulation or drug-induced periungual granulation under specialist guidance; not a substitute for definitive surgery in idiopathic stage III disease.

Procedural management — partial nail avulsion

Partial nail avulsion is the workhorse intervention. Performed under digital ring block with plain lidocaine (avoid adrenaline–epinephrine in some local protocols, although modern evidence supports cautious use of plain or low-dose epinephrine in selected adults), with a suitable digital tourniquet, the offending lateral 3–5 mm of nail plate is freed from the nail bed with a Freer elevator, divided longitudinally with English nail splitter or Beaver blade, and removed with mosquito forceps. Granulation tissue is curetted; chemical matricectomy follows.

Chemical matricectomy

• Phenol 88% applied with a fine-tipped applicator under tourniquet for two to three 30-second cycles; alcohol or copious saline neutralisation; the most studied option, with the strongest long-term recurrence data.
• Sodium hydroxide 10% applied for ~60 seconds with vinegar (acetic acid) neutralisation; comparable recurrence in trial data with possibly faster healing in some series.
• Recurrence: roughly 4–14% with chemical matricectomy versus 30–70% with simple avulsion alone or surgical wedge resection without matrix ablation.

Alternative or adjunctive surgical procedures

• Surgical (Winograd) wedge resection with sharp matricectomy—an alternative when phenol is unavailable or the lateral wall needs structural reduction; higher post-operative discomfort and longer healing in many series.
• Total nail avulsion—reserved for severe pincer-nail anatomy or pan-fold disease; carries high recurrence without matricectomy.
• Vandenbos procedure—lateral wall soft-tissue excision with preservation of the entire nail; selected centres; longer healing and less commonly used.

Antibiotics — stewardship rather than reflex

Cochrane and family-medicine evidence show that adding oral antibiotics to partial nail avulsion does not improve healing in immunocompetent adults with localised infection. Reserve systemic cover for spreading cellulitis, lymphangitis, systemic features, immunosuppression, diabetic-foot pathway or where definitive surgery will be delayed. When oral cover is needed, target Staphylococcus aureus and streptococci first-line:

• Cephalexin or amoxicillin ± clavulanate as per local antibiogram for non-MRSA disease.
• Clindamycin for penicillin allergy or MRSA risk; doxycycline as an alternative outpatient option.
• Cefuroxime for selected ambulatory disease where broader cover is appropriate.
• Topical mupirocin or fusidic acid is reasonable for limited periungual colonisation; topical antibiotics are not a substitute for procedural management of stage II–III disease.
• Anaerobic cover (e.g. add metronidazole) for deep diabetic-foot infections where polymicrobial flora is likely; let local guidance and culture results lead.

Tetanus and post-procedural cover

Update tetanus immunisation per CDC and NHS schedules when there is open skin breakdown and uncertain immunisation history. Plan a 24-hour dry dressing then daily warm soaks of 10–15 minutes followed by clean dressing changes; topical antibiotics are generally unnecessary after phenolisation and may sensitise. Footwear should be open or wide for at least 1–2 weeks; running and contact sport usually 2–4 weeks.

The patient who needs the most caution is the one most likely to under-report symptoms. Diabetic neuropathy, longstanding glucose dysregulation and peripheral arterial disease redraw the rules: the same lateral-fold spicule that resolves in two weeks for a healthy 17-year-old becomes the entry point for a deep tissue infection, osteomyelitis or frank limb-threatening ischaemia in a patient with poorly controlled type 1 diabetes or longstanding hypertension.

What flips the threshold

• Diabetes with neuropathy—loss of protective sensation, palpable nail-edge spicule with no pain, callus or ulcer at the lateral fold.
• Peripheral arterial disease—absent pedal pulses, ankle-brachial index <0.9, claudication, dependent rubor, dusky toe.
• Immunosuppression—steroids, biologics, chemotherapy, post-transplant therapy, advanced HIV.
• Healthcare-associated risk—recurrent admissions, prior MRSA, frequent antibiotics, residential-care residency.
• Suspected osteomyelitis—exposed bone on probe-to-bone test, ulcer >2 cm² or deeper than 3 mm, raised inflammatory markers, indolent course.

Pathway expectations

• Same-day diabetic-foot multidisciplinary review (or equivalent specialist team) per NICE NG19 expectations; do not sit on a poorly perfused foot over a weekend.
• Document pulses, sensation (10 g monofilament, vibration), capillary refill, skin temperature and any ulcer measurement in millimetres.
• Send wound culture, CBC, CRP and glucose; check HbA1c if not recent.
• Hold opportunistic nail surgery until perfusion and infection are characterised; instrumenting an ischaemic toe risks unmasking gangrene.
• Engage podiatry, vascular surgery and orthopaedics early; consider sepsis screening if systemic features.

Antibiotic considerations

Diabetic foot infections are commonly polymicrobial and frequently include anaerobes; broader cover is often warranted. Apply local guidance and IDSA-aligned protocols rather than the simple Staphylococcus-first recipe used in healthy adults; structured sepsis screening at presentation catches the deteriorating patient earlier than waiting for fever.

• Pre-procedure check. Confirm allergies, anticoagulation, infection control needs, paediatric or learning-disability adjustments and local procedure list eligibility; perform structured hand hygiene and aseptic technique before any instrumentation.
• Local anaesthetic safety. Calculate maximum dose of plain lidocaine (typically up to 4.5 mg/kg, ≤300 mg total in adults), warm and buffer the syringe to reduce sting, allow 5–10 minutes for full block, and mark which toe before any blade contact. Treat high-risk medications like phenol with double-check protocols.
• Consent and expectation setting. Document recurrence rates by technique, post-operative pain expectation, healing timescales, footwear modification, time off work and the small risk of cosmetic nail change after matricectomy.
• Tourniquet discipline. Document tourniquet on/off times; remove before the patient leaves the chair; never leave a digital tourniquet in place beyond 15–20 minutes without explicit reassessment.
• Wound management. Apply a non-adherent dressing after haemostasis; bulky dressings encourage residual bleeding pressure but should not constrict the digit. Use wound irrigation with normal saline at first dressing change rather than aggressive scrubbing.
• Pain control. Schedule rather than reactive analgesia for the first 24 hours; warn that throbbing pain that worsens after 48 hours is not normal and warrants review. Use a structured pain assessment at each follow-up encounter.
• Follow-up and documentation. Review at 7–14 days; photograph the wound at baseline and follow-up where consent allows; record stage at presentation, technique used, complications and outcome at 3–6 months for audit. Use a structured skin assessment to capture lateral fold and adjacent toe changes.
• Patient education that sticks. Demonstrate—do not just describe—straight nail trimming, footwear assessment and the soak-and-wick routine; written safety-netting with red-flag symptoms; clear escalation contact for the first 72 hours.
• Service-level audit. Recurrence at 6 months, infection rate, return-to-work time and patient-reported outcomes give the most useful quality signal in nail surgery clinics.

Vital signs

• Structured vital signs at presentation when systemic features or high-risk host are present; NEWS2 or equivalent for ward patients.
• Heart rate, blood pressure, respiratory rate and temperature documented in the same observation set; flag tachycardia, fever or hypotension.
• Capillary glucose for diabetic patients before and after any procedural intervention.

Targeted toe assessment

• Affected fold (lateral, medial, both), staging note and comparison photograph where consent allows.
• Pulses (dorsalis pedis, posterior tibial), capillary refill, skin temperature and colour with structured Doppler pulse assessment when palpation is uncertain.
• Sensation testing with 10 g monofilament and vibration if neuropathy is suspected.
• Granulation tissue, discharge character and lateral wall hypertrophy.
• Lymphangitic streaking proximal to the toe; mark leading edge of erythema with date and time.

Red flags requiring escalation

• Spreading erythema beyond the toe joint, lymphangitic streaks or systemic features.
• Pain disproportionate to skin findings, dusky bullae, crepitus or rapidly evolving deterioration.
• Pulseless cool dusky toe; new ischaemic features.
• Exposed bone on probe-to-bone or persistent purulent discharge despite a course of antibiotics.
• New or worsening hyperglycaemia in a diabetic patient with active infection.

Untreated or under-treated disease

• Recurrent infection, chronic granulation tissue and lateral wall hypertrophy.
• Cellulitis, lymphangitis and rarely systemic infection or osteomyelitis—particularly in diabetic and immunosuppressed feet.
• Adaptive antalgic gait, contralateral pain, falls and reduced activity.
• Toe-tip ulceration in patients with peripheral neuropathy.
• Workdays lost, school absence, impaired sport participation.

Procedure-related complications

• Pain, bleeding, bruising and slow re-epithelialisation; usually self-limiting.
• Persistent serous drainage after phenolisation—expected in the first 1–3 weeks; avoid premature antibiotics.
• Cosmetic nail-plate narrowing after matricectomy; rare nail-plate dysmorphism.
• Periostitis, osteitis or rarely osteomyelitis from over-aggressive curettage in fragile feet.
• Recurrence—typically 4–14% with chemical matricectomy, higher with avulsion-only techniques.
• Local anaesthetic toxicity if dose limits or technique are mishandled.
• Digital ischaemia from poorly applied tourniquet—preventable with disciplined timing and removal.

Prevention is dominated by trimming technique, footwear and foot hygiene rather than supplements or topical agents. Coach a straight-cut trim flush with the distal nail tip and explicitly discourage curved cuts and corner picking; recommend a wider toe box, breathable footwear and moisture-wicking socks for athletes. Identify and treat concurrent tinea pedis and onychomycosis. In adolescents with recurrent unilateral disease, low-threshold referral for definitive matricectomy avoids years of intermittent presentations and antibiotic exposure. In diabetic patients, embed nail and footwear review into routine annual foot screening with the diabetes team, and arrange podiatry-led trimming where the patient cannot self-manage safely.

Outcomes are generally excellent in immunocompetent adults. Stage I disease usually settles within 2–3 weeks of disciplined conservative care; partial nail avulsion with phenolisation has a 4–14% recurrence rate at one year and a high patient satisfaction profile. Most adults return to desk work within 24 hours, walking activity within 1–2 weeks, and contact sport within 2–4 weeks. Cosmetic nail narrowing after matricectomy is well tolerated. Prognosis worsens sharply when diabetes, peripheral arterial disease or immunosuppression are present—amputation rates climb when ingrown toenail is treated as a stand-alone nail problem rather than as a marker of broader foot risk. Long-term outlook in chronic stage III disease without matricectomy is poor; serial avulsions without matrix ablation buy weeks but not durable resolution.

Subtle deterioration

The toe that worsens between two appointments rarely shouts. Watch for a creeping outline of erythema, increased throbbing on dependent positioning, the patient who quietly stops weight-bearing on the heel, and the diabetic foot whose better toe coincides with falling sensation rather than improving healing. None of those points alone trigger an emergency call, but pattern recognition reaches for a senior review and vascular assessment before the toe changes colour.

Communication friction

Patients often arrive after months of self-management or repeated antibiotic courses; meet that fatigue with a calm explanation of why staging matters, and what a procedural answer can offer that another bottle of antibiotics cannot. Adolescents may be embarrassed about their feet and pedicure habits; create privacy and avoid moralising language. Diabetic patients may have heard foot care so often it has lost meaning—anchor the conversation in concrete actions and clear escalation contacts.

Bedside checklist

• Stage the toe before you treat it; document Heifetz and host risk in the same line.
• Photograph the lateral fold at baseline and follow-up where consent allows.
• Mark the leading edge of erythema with date and time when escalation is in question.
• Audit your last six recurrences—were they avulsion-only, missed matricectomy, or comorbid feet that needed a different pathway?

Initial bundle: ABCDE primary survey if systemically unwell; secure IV access; bloods including CBC, CRP, glucose and lactate; wound swab before antibiotics where feasible; broad-spectrum intravenous antibiotics per local sepsis protocol when systemic infection is suspected; mark the leading edge of erythema; analgesia; podiatry, vascular and surgical input as relevant; and document escalation time stamps so the next clinician inherits a usable picture.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze completion on the topic of onychocryptosis—Heifetz staging, soak-and-wick technique, partial nail avulsion with phenolisation, antibiotic stewardship and the diabetic-foot escalation pathway—mapped to the Clinical Judgment Measurement Model layering of cues before action.